Vaxart, Inc., a biotechnology company specializing in the development and marketing of oral flu vaccines, has recently announced a significant financial development. On April 17, 2026, the company filed a current report detailing its entry into a share purchase agreement with Lincoln Park Capital Fund. This strategic move allows Vaxart the option, at its discretion, to sell up to approximately $25 million of its common stock over a 24-month period.
The agreement is structured to provide Vaxart with flexible capital-raising support, crucial for its ongoing clinical and strategic initiatives. Importantly, Vaxart retains full control over the timing and quantity of the stock sales. Lincoln Park Capital Fund, on the other hand, is obligated to purchase the shares at prices tied to prevailing market levels. Additionally, the investor is restricted from short-selling or hedging the stock, ensuring a stable investment environment.
The transaction is designed to leverage exemptions from registration requirements, simplifying the process for both parties. A registration-rights agreement is included, stipulating that a registration statement covering the resale by Lincoln Park must become effective before any shares are sold. Notably, the agreement does not include any warrants or rights of first refusal, further emphasizing the straightforward nature of the deal.
Vaxart, Inc., headquartered in South San Francisco, USA, continues to serve its global customer base through its website, www.vaxart.com . The company trades on the Nasdaq stock exchange and has a market capitalization of $175.18 million as of April 16, 2026. With a close price of $0.75 on the same date, Vaxart’s stock has experienced fluctuations over the past year, reaching a 52-week high of $0.84 on January 11, 2026, and a low of $0.26 on July 8, 2025. The company’s price-to-earnings ratio stands at 11.46, reflecting its current market valuation.
This financial maneuver underscores Vaxart’s commitment to advancing its innovative oral flu vaccine technology, which stimulates the immune system of the gut to generate both systemic and mucosal immune responses. As the company continues to navigate the competitive biotechnology landscape, this agreement with Lincoln Park Capital Fund positions Vaxart to further its clinical and strategic goals, reinforcing its role as a key player in the health care sector.
